Short answer
Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Lucid Diagnostics announced fiscal quarter results for the period ended September 30, 2026.
Lucid Diagnostics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Lucid Diagnostics announced fiscal quarter results for the period ended September 30, 2026
- Business update included alongside the quarterly financial release
- Exhibit 99.1 contains the detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Nationwide Medicare reimbursement at $1,938.01 per EsoGuard test removes a major commercialization barrier
- Record October volume exceeded 1,800 tests after 2,871 tests in 3Q26, signaling early acceleration but requiring revenue conversion
- 3Q26 revenue $1.2M, operating expenses $13.5M, GAAP net loss $6.7M, or $(0.03) per share
- Cash $18.0M at September 30, supplemented by a subsequent $15.0M Series C preferred financing
- MolDX LCD reconsideration remains pending, while five Concert health plans are expected to adopt coverage by year-end
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lucid Diagnostics Inc. 8-K filings
Get the next LUCD 8-K as it lands
Follow LUCD for push alerts, or ask the research agent what this filing means.